Business Development & Valorization
Accelerating Innovation in Regenerative Medicine
-
At RegMed XB, we turn cutting-edge research, enabling technologies, and novel therapies into viable businesses. Through strategic partnerships with established companies and high-potential start-ups, we help bring regenerative medicine innovations to patients faster.
TTT Innovation Vouchers for Life Sciences & Health
The Thematic Tech Transfer (TTT) Program, funded by RVO, is a key component of RegMed XB’s valorization and tech-transfer activities. The TTT Program aims to create investable academic spinoffs in the field of chronic diseases. In collaboration with the Dutch CardioVascular Alliance (DCVA), BioGeneration Ventures (BGV), and leading health foundations: the Dutch Heart Foundation, Kidney Foundation, Brain Foundation, and Diabetes Fund, we strengthen the pathway from scientific discovery to societal and clinical impact.
We bring science and entrepreneurship together by:
- Organizing (Valorization) Community events
- Educating researchers and policy makers
- Supporting researchers in commercializing their inventions
Our Impact Officers actively scout for high-impact research with spinoff potential in the field of chronic diseases and guide research teams through the world of technology transfer and academic entrepreneurship.
Together with BGV and its fund FIRST II, we review promising projects to identify the key next steps required to build a compelling business case and attract investment for spinoff creation and further development of the technology.
-
Our Valorization Services include:
- Strategic and business development advice
- Access to a strong innovation and industry network
- Financial support through innovation vouchers
- Guidance on start-up creation and market validation
We help innovators at every step — from evaluating early business ideas to bringing regenerative medicine solutions to the market.
What researchers gain through TTT:
- Expert scientific, entrepreneurial, and strategic guidance
- Support to assess the clinical, societal, and commercial potential of innovations
- Preparation for next development steps, including making projects investment-ready
Why Work with RegMed XB?
- Deep expertise in regenerative medicine commercialization
- Established network across academia, industry, and clinical partners
- Proven track record in accelerating start-ups and spin-offs
- Strong national partnerships through TTT and DCVA
We empower innovators to turn breakthrough science into therapies, technologies, and businesses that deliver real impact.
-
Examples of entrepreneurial teams RegMed XB helped:
From serendipity to startup: the story behind SBMatrices
What began as an accidental discovery in a chemistry lab has evolved into a deeptech venture with the potential to significantly impact organoid research and regenerative medicine.
read more
XS Innovations bringing a new standard to dialysis care
XS Innovations is tackling a major challenge for people with end-stage kidney disease: keeping their blood vessel access open for dialysis. Most patients need a special connection between an artery and a vein in their arm, called an arteriovenous fistula (AVF), to ensure enough blood flows during treatment.
read more
Hello R&D sets out to eliminate liver toxicity
Liver toxicity is the number one reason for drugs to be retracted from the market. More reliable methods for predicting drug- induced liver toxicity will not only save drug development costs by detecting liver toxic drugs earlier, but will also spare patients from potential severe side effects due to liver toxicity.
read more
Phlox Therapeutics, is developing RNA-based therapies for genetic cardiomyopathies
Phlox Therapeutics, is developing RNA-based therapies for genetic cardiomyopathies. Founded by Prof. Dr. Eva van Rooij and Prof. Dr. Yigal Pinto in 2022, the company has made significant progress with Dr. Margien Boels, PhD, as Chief Operating Officer.
read more -
Contact one of our Impact Officers
